Publications by authors named "Anne Rubarth"
Article Synopsis
- Metastatic clear cell renal cell carcinomas (ccRCCs) are tough tumors that don’t respond well to certain types of cancer treatments, making it hard for patients to get help.
- Researchers found that these tumors have a lot of DNA damage and can still respond to treatments that cause more damage.
- A new drug called M4344 showed promise by helping to stop ccRCC cell growth and working well with other cancer drugs to make treatments more effective.
The prognosis of AML patients with adverse genetics, such as a complex, monosomal karyotype and TP53 lesions, is still dismal even with standard chemotherapy. DNA-hypomethylating agent monotherapy induces an encouraging response rate in these patients. When combined with decitabine (DAC), all-trans retinoic acid (ATRA) resulted in an improved response rate and longer overall survival in a randomized phase II trial (DECIDER; NCT00867672).
View Article and Find Full Text PDF